Role of montelukast in asthma treatment in 2025

Rafał Pawliczak

doi:10.5114/pja.2025.147954

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2025
vol. 12

Send email

Copy url:

abstract:

Review paper

Role of montelukast in asthma treatment in 2025

Rafał Pawliczak

¹

Department of Immunopathology, Faculty of Medicine, Medical University of Lodz, Poland

Alergologia Polska – Polish Journal of Allergology 2025; 12, 1: 42–46

DOI: https://doi.org/10.5114/pja.2025.147954

Online publish date: 2025/02/28

View full text Get citation

PlumX metrics:

This review paper explores the role and significance of antileukotriene therapy in asthma management. It highlights the involvement of the arachidonic acid metabolite-dependent pathway, regardless of the formal phenotype and, in some cases, the endotype of asthma. The paper identifies scenarios where antileukotriene therapy serves as a valuable adjunct to existing treatments, regardless of disease severity. In addition, it examines the adverse effects of montelukast, with particular focus on unproven neuropsychiatric concerns. Overall, montelukast remains a safe and effective option in asthma treatment.

keywords:

Role of montelukast in asthma treatment in 2025

Rafał Pawliczak 1

asthma, montelukast, treatment

Rafał Pawliczak

¹